Evidence map›Paper›PMID 40182285›Full record

ArticleFrontiers in microbiology2025

Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant

Guangfen Wang, Hui Zhang, Qiaoping Wu, Jianqiang Xu, Xuedan Qiu, Jinyuan Chen, Fujie Cui, Jian Zhou, Qingcao Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Revisiting the Metallo-International journal of microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangfen Wang *Department of Hospital Infection-Control, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Hui Zhang *Department of Clinical Laboratory, Ninghai County Chengguan Hospital, Ningbo, China.
Qiaoping WuDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Jianqiang XuDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Xuedan QiuDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Jinyuan ChenDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Fujie CuiDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Jian ZhouDepartment of Clinical Infectious Disease, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.
Qingcao LiDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to investigate the synergistic effects and biofilm inhibition mechanisms of ceftazidime-avibactam (CZA) combined with aztreonam (ATM) against carbapenem-resistant Methods: We selected a total of 150 non-duplicate clinical isolates of CRKP from multiple hospitals in Ningbo. Common carbapenemase genes were detected using PCR. Broth microdilution and time-kill assays were used to evaluate the Results: The comparison of synergistic indices for different enzyme-type CRKP strains with CZA and ATM combination therapy showed a statistically significant difference ( Conclusion: The combination of ATM and CZA shows a strong synergistic antibacterial effect against CRKP strains with various enzyme types, with particularly notable synergy in strains carrying the

Indexed as

aztreonamcarbapenemaseceftazidime-avibactamcombined drug sensitivityCRKP

Identifiers

PMID40182285
PMCPMC11965359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.